Sign Up! | Tags | Domains | Statistics | Options | Advanced Search
|
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
istockanalyst.com » Aerospace: iStockAnalyst.com Feed - Nov 10, 2008
The past two weeks were anything but easy for Rigel’s (RIGL) shareholders, who saw their shares crash more than 50%. Rigel started 2008 on the right foot after a 200% jump in a single day last December, following …
Also tagged: abt, jnj, pfe, amgn, wye, gild, agn, cvtx, rosg, incy, rigl
 |
Rigel Pharmaceuticals: Biotech Crisis or Opportunity?seekingalpha.com » SeekingAlpha.com: Home Page - Nov 10, 2008 Ohad Hammer submits: The past two weeks were anything but easy for Rigel’s (RIGL) shareholders, who saw their shares crash more than 50%. Rigel started 2008 on the right foot after a 200% jump in a single day last … Also tagged: abt, jnj, pfe, amgn, wye, gild, agn, cvtx, rosg, incy, ohad hammer, rigl |
streetinsider.com » StreetInsider.com News Articles - Oct 30, 2008
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Poniard+Pharmaceuticals+%28PARD%29+Reports+Q3+Loss+of+36c/4111366.html for the full story.
istockanalyst.com » Podcast: iStockAnalyst.com Feed - Oct 10, 2008
History has shown again and again that times like these represent a huge long term buying opportunity. This may be particularly true for the biotech segment that, despite weathering the storm better than other …
Also tagged: dna, amgn, miti, gild, bbi, sgen, exel, snta, rosg, arry, arql, imgn, rigl
seekingalpha.com » Long Investment Ideas from Seeking Alpha - Oct 10, 2008
Ohad Hammer submits: History has shown again and again that times like these represent a huge long-term buying opportunity. This may be particularly true for the biotech segment that, despite weathering the storm …
Also tagged: dna, amgn, nvs, gsk, alth, miti, isis, gild, sgen, alny, cvtx, bbh, exel, snta, rosg, arry, xbi, arql, ohad hammer, imgn, rigl, mbrk
bizjournals.com » Latest news from San Francisco Business Times - Oct 6, 2008
Poniard Pharmaceuticals Inc. will take a $10 million cash advance — its second in five weeks — from a line of credit it secured early last month. (PARD)
bizjournals.com » National Business News - Local Business News | bizjournals - Sep 3, 2008
Poniard Pharmaceuticals Inc. borrowed $27.6 million from GE Healthcare Financial Services and Silicon Valley Bank. (PARD)
streetinsider.com » StreetInsider.com News Articles - Jul 31, 2008
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Poniard+Pharmaceuticals+%28PARD%29+Reports+Q2+Loss+of+%240.36%2C+Misses+by+5c/3866738.html for the full story.
seekingalpha.com » SeekingAlpha.com: Home Page - Jun 24, 2008
Ohad Hammer submits: This article will discuss the development of Poniard’s lead drug, picoplatin, for the treatment of small cell lung cancer [SCLC]. A General introduction for picoplatin can be found in the first …
Also tagged: gsk, celg, infi, exel, ohad hammer
istockanalyst.com » Economics Data: iStockAnalyst.com Feed - Jun 22, 2008
Poniard Pharmaceuticals – Platinum Rediscovered (Part II)[More...]
Also tagged: gsk, celg, exel, ohad hammer